Pacific Biosciences Sequel II System
Pacific Biosciences has launched it Sequel II single-molecule sequencing instrument. The new system runs SMRT chips that contain 8 million wells, or zero-mode waveguides (ZMWs). The system delivers around eight times greater data output than the firm's original Sequel instrument, which had 1 million ZMWs. According to the company, its HiFi reads, which make use of PacBio's circular consensus sequencing (CCS) protocol, have greater than 99.9 percent accuracy. As of last month, five early access customers had run 58 SMRT cells, obtaining average yields per SMRT cell for the CCS protocol of 250.4 gigabases and average per-cell yields for its continuous long read protocol of 67.4 gigabases.
Cell Microsystems AIR Software Update, HexaQuad Array
Cell Microsystems has released new software for its AIR System, automating cloning workflows by using brightfield imaging to eliminate the need for fluorescent markers for sorting and confluency measurement. In addition, another new feature automates cell-sorting based on fluorescent signal intensities to characterize complex phenotypes.
Cell Microsystems has also launched the HexaQuad array, which it has designed to simultaneously run 24 distinct experiments on a single consumable. The firm said that the array is suited for labs who perform high-throughput CRISPR editing in single guide or guide pools, which allows for scaling of hundreds of clones per week and reducing a two-month workflow. Combined with the new software, the array provides a five-day workflow for researchers.
Human Diagnostics Worldwide, Eiken Chemical, FIND Malaria-LAMP
Human Diagnostics Worldwide, Eiken Chemical, and the Foundation for Innovative New Diagnostics launched Malaria-LAMP for the detection of malaria caused by Plasmodium vivax parasites. The group said that it is the first commercially available molecular test for P. vivax-associated malaria. The assay uses loop-mediated isothermal amplification developed by Eiken and is exclusively distributed by Human Diagnostics. FIND and the Hospital for Tropical Diseases evaluated the prototype test and coordinated in-country clinical performance studies in Columbia and Peru. The test can differentiate between Plasmodium pan species, P. falciparum, and P. vivax, and has a sensitivity of 84 percent to 94 percent and a specificity of greater than 92 percent. According to the group, the assay's limit of detection is one to two parasites per microliter.
For more new products and services, please visit the New Products page on our website.